 Capricor Therapeutics Inc NASDAQ: CAPR has partnered with Nippon Shinyaku Co Ltd for the exclusive commercialization and distribution in the U.S of Capricors CAP-1002 for Duchenne muscular dystrophy DMD. Capricors proprietary cell therapy, CAP-1002, comprises human allogeneic cardiosphere-derived cells. 